Mizuho Raises MiniMed Group (NASDAQ:MMED) Price Target to $26.00

MiniMed Group (NASDAQ:MMED) had its price target hoisted by research analysts at Mizuho from $21.00 to $26.00 in a research note issued to investors on Wednesday, Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Mizuho’s price objective suggests a potential upside of 15.97% from the stock’s current price.

Several other research analysts also recently issued reports on the company. Piper Sandler reaffirmed a “neutral” rating and issued a $16.00 price objective on shares of MiniMed Group in a research note on Thursday, June 4th. BTIG Research upped their price target on shares of MiniMed Group from $25.00 to $28.00 and gave the company a “buy” rating in a research report on Tuesday. Wells Fargo & Company cut their price target on shares of MiniMed Group from $26.00 to $22.00 and set an “overweight” rating on the stock in a report on Thursday, June 4th. Benchmark reaffirmed a “buy” rating on shares of MiniMed Group in a research report on Thursday, June 4th. Finally, Weiss Ratings raised MiniMed Group from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, July 20th. Thirteen research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $22.85.

MiniMed Group Price Performance

Shares of MMED stock opened at $22.42 on Wednesday. MiniMed Group has a twelve month low of $10.65 and a twelve month high of $22.74. The stock’s fifty day moving average price is $17.65. The company has a market cap of $6.31 billion and a price-to-earnings ratio of -32.97.

MiniMed Group (NASDAQ:MMED) last posted its earnings results on Wednesday, June 3rd. The company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.46). The business had revenue of $837.00 million during the quarter. MiniMed Group’s quarterly revenue was up 15.6% on a year-over-year basis. On average, sell-side analysts anticipate that MiniMed Group will post 0.66 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. California State Teachers Retirement System acquired a new stake in MiniMed Group in the second quarter worth $89,000. Legal & General Group Plc bought a new stake in MiniMed Group in the 2nd quarter valued at about $91,000. The Manufacturers Life Insurance Company acquired a new position in MiniMed Group during the 2nd quarter worth approximately $185,000. Punch & Associates Investment Management Inc. acquired a new stake in MiniMed Group in the second quarter valued at approximately $292,000. Finally, Washington Growth Strategies LLC acquired a new position in shares of MiniMed Group during the second quarter worth approximately $397,000.

Trending Headlines about MiniMed Group

Here are the key news stories impacting MiniMed Group this week:

• Positive Sentiment: MiniMed reported fiscal Q1 2027 net sales of $843 million, up 17% year over year, with organic U.S. sales growth accelerating to 13% and international sales rising 18% as reported. Earnings per share also exceeded analyst expectations. MiniMed Delivers Strong Start to Fiscal Year 2027 with U.S. Growth Acceleration
• Positive Sentiment: Management raised its fiscal 2027 organic revenue-growth guidance, signaling confidence that recent momentum can continue. The company also said its product pipeline is progressing ahead of schedule, including FDA submission plans for MiniMed Fit™, CE Mark progress for MiniMed Flex™, completion of enrollment in the Vivera™ FCL U.S. pivotal trial, and IDE approval for a next-generation extended-wear sensor. MiniMed Group Releases Q1 2027 Financial Results
• Positive Sentiment: BTIG Research raised its price target to $28 from $25 and maintained a “buy” rating, reflecting expectations for further upside based on the company’s growth outlook. MiniMed Group Price Target Increase
• Neutral Sentiment: The earnings call highlighted the quarter’s performance and pipeline developments, giving investors additional detail on the company’s operating outlook. MiniMed Group Q1 2027 Earnings Call Transcript
• Negative Sentiment: The consensus broker price target is $21.62, below the stock’s recent quoted level, suggesting that some analysts see limited near-term upside despite the improved operating results. MiniMed Group Receives Consensus Target Price

MiniMed Group Company Profile

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.